Frontage Expands Early Drug Discovery Services through the Acquisition of Heyan Biotech
On September 8, 2021, Frontage Shanghai announced its acquisition of a 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd. This strategic move aims to enhance Frontage's early drug discovery services, leveraging Heyan Biotech's expertise in pharmacodynamic screening and biological assay development. Heyan Biotech collaborates closely with various drug companies and academic institutions, offering technologies that will complement Frontage's existing services. The acquisition positions Frontage to expand its service capacity, particularly in areas like neuropathy, cancer, and metabolic diseases.
- Acquisition of 70% of Heyan Biotech enhances Frontage's drug discovery capabilities.
- Heyan Biotech's established collaborations strengthen Frontage's market position.
- Expansion into new technology platforms increases service offerings in drug discovery.
- None.
Insights
Analyzing...
SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Frontage Shanghai announced the acquisition of
Heyan Biotech, located in Wuhan Optics Valley, national biotech industry base, provides for target based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic evaluation services in early drug discovery. Technical capabilities include screening of drug targets, customized biological assay development and detection services.
The Heyan team has been deeply engaged in the biological CRO industry for many years, consistently adhering to the customer value orientation, win-win cooperation and helping new drug research and development.
Dr Song Li, Chairman and CEO of Frontage, said: "Heyan Biotech mainly provides drug discovery services such as drug activity screening and kinase function test, it has established close research collaborations with many innovative drug companies, well-known universities and scientific research institutes. Its technology platforms as well as talents could effectively complement the existing service lines of Frontage. Based on the existing testing services, Heyan Biotech will focus on expanding the application of SPR technology, Protac technology, ion channels, GPCR targets, intracellular kinase binding evaluation and high connotation technology detection platform. It will comprehensively cover the fields of neuropathy, metabolic diseases, inflammation, cancer and safety evaluation targets. Heyan Biotech will further expand its service capacity in drug discovery to enhance Frontage's one-stop service capacity and capability in the field of drug discovery and development."
About Frontage Holdings Corporation
Frontage Holdings Corporation is a fast-growing CRO in the provision of integrated, science-driven research, analytical and development services throughout the product discovery and development process to enable biopharmaceutical and life science companies to achieve their product development goals. The Company benefits greatly from having operations in both North America (including the U.S. and Canada) and China, and is well placed to capture growth opportunities in both markets.
Contact: Bryan Newman, bnewman@frontagelab.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/frontage-expands-early-drug-discovery-services-through-the-acquisition-of-heyan-biotech-301371312.html
SOURCE Frontage Laboratories, Inc.
FAQ
What is the purpose of Frontage's acquisition of Heyan Biotech?
When was the acquisition of Heyan Biotech by Frontage announced?
How will the acquisition impact Frontage's service capacity?
What technologies will Heyan Biotech bring to Frontage?
What percentage of Heyan Biotech does Frontage now own?
